Noxxon reveals results from PHASE 1/2 trial of NOX-A12/KEYTRUDA®
Category: #health  By Mateen Dalal  Date: 2019-10-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Noxxon reveals results from PHASE 1/2 trial of NOX-A12/KEYTRUDA®

Colorectal cancer (CRC), also known as bowel or colon cancer, is a type of cancer that involves abnormal growth of cells that can invade or spread to other parts of the body. Growing prevalence of CRC has led various pharmaceuticals firms to develop novel drugs using advanced research and clinical trials.

NOXXON Pharma N.V. is one such firm that develops innovative cancer treatments and has recently announced new clinical findings from the Phase 1/2 trial of NOX-A12 paired with Keytruda® (pembrolizumab) in patients suffering from microsatellite-stable, metastatic colorectal and pancreatic cancer.

Reportedly, the data was presented at the ESMO (European Society for Medical Oncology) Congress 2019, held in Spain.

According to reliable sources, the combination of pembrolizumab and NOX-A12 showed stable disease in 25% of patients, induced an immune response and sustained time on treatment, compared to previous therapy for 35% of patients. Moreover, constant follow-up of patients has established an overall survival statistic of 22% at 12 months and 42% at 6 months.

Speaking on the development, Aram Mangasarian, CEO, NOXXON, said that both metastatic pancreatic and colorectal cancers have a very limited remedial alternative. However, the positive results from the clinical data and the fact that three heavily pre-treated patients lived over a year reinforces the capability of NOX-A12 to target the tumor microenvironment.

Incidentally, in addition to the positive outcomes, the company has also prior achieved a monumental landmark when it completed the capital increase of €1 million which was previously halted. Noxxon has also revealed that its future investments are fixed for the upcoming investment round.

Commenting on the attained capital, Mangasarian said that the company is delighted to reveal the conclusion of the capital increase which has positioned itself at a secure position which would ensure the progression and beginning of Phase 1/2 clinical study in brain cancer.

Noxxon is also dedicated towards building the clinical studies sites in Germany where the trial was given a green signal by the Ethics Committees and regulatory authorities, he added.

Source Credit: https://www.noxxon.com/downloads/pressrel/2019-09-29_ESMO_Poster_PR_EN.pdf

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Stocks of luxury fashion houses raise in response to China’s reopening
Stocks of luxury fashion houses raise in response to China’s reopening
By Mateen Dalal

Luxury fashion houses dependent on Chinese customers reportedly saw a hike in stocks as China reopens, however, those clients may not necessarily be purchasing the goods elsewhere. In the past, wealthy Chinese customers would frequently buy person...

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...